Phase 1/2 Master Protocol for Open-Label, Multi-Centre, Single-Arm, Sub-Studies, First in Human Clinical Studies of TCR-T Therapy (Autologous TCR-Modified T-Cell Therapy) Targeting Mutated Kirsten Rat Sarcoma (mutKRAS) Administered in Metastatic or Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Adult Patients with Specific mutKRAS and Human Leukocyte Antigen (HLA) Genotypes.
Phase 1/2 Master Protocol for Open-Label, Multi-Centre, Single-Arm, Sub-Studies, First in Human Clinical Studies of TCR-T Therapy (Autologous TCR-Modified T-Cell Therapy) Targeting Mutated Kirsten Rat Sarcoma (mutKRAS) Administered in Metastatic or Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Adult Patients with Specific mutKRAS and Human Leukocyte Antigen (HLA) Genotypes.
